Trials / Withdrawn
WithdrawnNCT05379907
Observational Study of ctDNA in Resectable and Borderline Resectable Pancreatic Cancer
- Status
- Withdrawn
- Phase
- —
- Study type
- Observational
- Enrollment
- 0 (actual)
- Sponsor
- Inova Health Care Services · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to collect information about treatment recommendations based on ctDNA testing and whether treatment changes based on ctDNA information result in better outcomes for patients with pancreatic cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | SIGNATERA™ ctDNA testing | Information collection about how SIGNATERA™ ctDNA testing changes how doctors make treatment recommendations to patients with early-stage pancreatic cancer. |
Timeline
- Start date
- 2022-08-23
- Primary completion
- 2023-08-23
- Completion
- 2023-08-23
- First posted
- 2022-05-18
- Last updated
- 2023-09-06
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05379907. Inclusion in this directory is not an endorsement.